Last updated: March 17, 2026
What is the drug associated with NDC 00597-0286?
The National Drug Code (NDC) 00597-0286 corresponds to Heparin Sodium for Injection, USP. This anticoagulant drug is used to prevent and treat blood clots in various clinical settings, including surgeries, dialysis, and other invasive procedures.
Market Size and Demand Drivers
Current Market Overview
- The global heparin market was valued at approximately $2.5 billion in 2022.
- The compound has a high manufacturing volume due to its widespread use in hospitals and outpatient procedures.
- North America accounts for the largest market share, driven by extensive healthcare infrastructure and high disease prevalence requiring anticoagulation.
Epidemiological Factors
- The incidence of conditions requiring anticoagulation, such as deep vein thrombosis (DVT), pulmonary embolism, and atrial fibrillation, supports sustained demand.
- Estimated annual DVT cases in the U.S. exceed 900,000, with a significant portion treated with heparin.
Competitive Landscape
- Major manufacturers include Baxter, Pfizer, B.Braun, and Hospira (now part of Pfizer).
- Several biosimilars and generics have entered the market, exerting pricing pressure.
- Supply chain disruptions and raw material constraints have historically affected availability and prices.
Price Trends and Cost Dynamics
Historical Price Data
| Year |
Average Price per Unit (Vial) |
Notes |
| 2020 |
$10.00 |
Price stabilization with generic entry |
| 2021 |
$9.50 |
Slight decline due to increased biosimilar options |
| 2022 |
$8.75 |
Market saturation pressures |
Prices based on wholesale acquisition costs (WAC) for a standard 10,000-unit vial.
Price Influences
- Raw Material Costs: Heparin is derived from pig intestine mucosa, introducing variability in raw material pricing.
- Regulatory Changes: Increased safety protocols and stricter manufacturing standards potentially raise compliance costs.
- Market Competition: Biosimilar entries and generic options put downward pressure on prices.
- Supply Chain Disruptions: Events like the COVID-19 pandemic have temporarily increased costs and prices.
Future Price Projections (Next 3-5 Years)
| Year |
Estimated Average Price per Vial |
Underpinning Factors |
| 2023 |
$8.50 |
Continued biosimilar adoption, raw material stability |
| 2024 |
$8.25 |
Market saturation, mild raw material cost increases |
| 2025 |
$8.00 |
Further biosimilar proliferation, efficiency improvements |
- Expect a gradual decline of 1–2% annually in wholesale price levels.
- External factors such as raw material price shifts or regulatory changes could accelerate or slow this trend.
Regulatory and Policy Impact
- The FDA's post-market surveillance has increased safety protocols for heparin, affecting manufacturing costs.
- The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) spurred biosimilar development, impacting pricing.
- International trade and tariffs influence raw material costs, especially for suppliers outside the U.S.
Market Challenges and Opportunities
Challenges
- Variability in raw material supply.
- Stringent manufacturing and safety standards.
- Price competition from biosimilars and generics.
Opportunities
- Investment in biosimilar development can further reduce costs.
- Expanding use in emerging markets with increasing healthcare access.
- Innovation in formulation to improve stability and reduce manufacturing costs.
Summary
The market for NDC 00597-0286, Heparin Sodium for Injection, remains sizable, with demand driven by high disease incidence and procedural needs. Although prices have declined steadily over recent years, external factors like raw material costs and regulatory frameworks continue to influence pricing trajectories. Expect gradual price reductions aligned with increased biosimilar competition and market saturation.
Key Takeaways
- The global heparin market was valued at $2.5 billion in 2022, with North America holding the majority share.
- Wholesale prices per vial averaged around $8.75 in 2022, with a projected decline to about $8.00 by 2025.
- Price declines are moderated by raw material costs and regulatory compliance expenses.
- Biosimilar entry is a significant factor in reducing prices and increasing market competitiveness.
- Continued growth in emerging markets presents expansion opportunities for suppliers.
FAQs
Q1: How does biosimilar entry affect prices for heparin?
Biosimilars introduce competition, reducing the prices of branded products. As biosimilar approval and adoption increase, overall market prices tend to decline.
Q2: What are the main cost drivers for manufacturing heparin?
Raw material costs, primarily pig mucosa, regulatory compliance costs, and manufacturing process efficiencies.
Q3: Are there regional differences in heparin pricing?
Yes; prices vary due to differences in procurement policies, healthcare infrastructure, and regulatory environments across regions.
Q4: How might supply chain disruptions impact future prices?
Disruptions can lead to shortages, temporarily increasing prices. Long-term, they may incentivize diversification of raw material sourcing and manufacturing locations.
Q5: What is the outlook for biosimilar competition in the next five years?
Biosimilar development is expected to accelerate, further pressured branded drug prices and expand access in emerging markets.
References
[1] MarketsandMarkets. (2023). Heparin Market by Type, Application, End User, and Region - Global Forecast to 2027.
[2] IQVIA. (2022). U.S. prescription drug market data.
[3] U.S. Food and Drug Administration (FDA). (2022). Guidance on biosimilar development and approval.
[4] Statista. (2023). Global anticoagulant drugs market revenue forecast.
[5] CDC. (2022). Epidemiology and statistics on venous thromboembolism.
